Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
2023年9月27日 - 5:10AM
Morphic Holdings Inc. (Nasdaq: MORF) today announced that
Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent
medical event and is taking a medical leave of absence. Dr.
Tipirneni is expected to return to his role as Chief Executive
Officer after he recovers. In the interim, Morphic’s executive
team, led by Dr. Bruce Rogers, President and Dr. Marc Schegerin,
COO and CFO, will continue with its leadership in day-to-day
operational activities on a normal basis.
“Praveen’s health and continued recovery is the
only focus for him and his family. We are sending them our thoughts
and support and we look forward to him returning in good health,”
said Gustav Christensen, Morphic’s Chairman of the Board of
Directors. “In the meantime, our highly seasoned and experienced
executives will work collaboratively, as always, to maintain
business operations and ensure that the Company’s strategic
objectives remain on track during Praveen’s leave.”
Morphic expects no interruptions or changes to
its business operations and will provide an update on Dr.
Tipirneni’s health as soon as is practicable. The Company remains
confident in its differentiated proprietary pipeline and MInT
platform technology to treat the high unmet need of serious chronic
diseases, including the development prospects for MORF-057 in
IBD.
About Morphic Holdings
Morphic Holdings is a biopharmaceutical
company developing a portfolio of oral integrin therapies for the
treatment of serious chronic diseases, including autoimmune,
cardiovascular, and metabolic diseases, fibrosis, and
cancer. Morphic is also advancing its pipeline and
discovery activities in collaboration with Schrödinger using its
proprietary MInT technology platform which leverages the Company’s
unique understanding of integrin structure and biology. For more
information, visit www.morphictx.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking”
statements within the meaning of the Securities Act of 1933, as
amended, the Securities Exchange Act of 1934, as amended, and of
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including, but not limited to: the company’s
management team and operational objectives. Statements including
words such as “believe,” “plan,” “continue,” “expect,” “will be,”
“develop,” “signal,” “potential,” “anticipate” or “ongoing” and
statements in the future tense are forward-looking statements.
These forward-looking statements involve risks and uncertainties,
as well as assumptions, which, if they do not fully materialize or
prove incorrect, could cause our results to differ materially from
those expressed or implied by such forward-looking statements.
Forward-looking statements are subject to risks and uncertainties
that may cause Morphic’s actual activities or results to differ
significantly from those expressed in any forward-looking
statement, including risks and uncertainties disclosed in this
press release and other risks set forth in our filings with the
Securities and Exchange Commission, including Morphic’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2022
filed with the SEC on February 23, 2023 and Quarterly Report on
Form 10-Q for the quarter ended June 30, 2023 filed with the SEC on
August 23, 2023. These forward-looking statements speak only as of
the date hereof and Morphic specifically disclaims any obligation
to update these forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by
law.
ContactsMorphic TherapeuticChris
Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
過去 株価チャート
から 5 2024 まで 6 2024
Morphic (NASDAQ:MORF)
過去 株価チャート
から 6 2023 まで 6 2024